Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial.
Fiche publication
Date publication
septembre 2024
Journal
Lancet (London, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr HEYD Bruno
Tous les auteurs :
Adam R, Piedvache C, Chiche L, Adam JP, Salamé E, Bucur P, Cherqui D, Scatton O, Granger V, Ducreux M, Cillo U, Cauchy F, Mabrut JY, Verslype C, Coubeau L, Hardwigsen J, Boleslawski E, Muscari F, Jeddou H, Pezet D, Heyd B, Lucidi V, Geboes K, Lerut J, Majno P, Grimaldi L, Levi F, Lewin M, Gelli M,
Lien Pubmed
Résumé
Despite the increasing efficacy of chemotherapy, permanently unresectable colorectal liver metastases are associated with poor long-term survival. We aimed to assess whether liver transplantation plus chemotherapy could improve overall survival.
Mots clés
Humans, Liver Transplantation, Middle Aged, Liver Neoplasms, secondary, Male, Female, Colorectal Neoplasms, pathology, Prospective Studies, Adult, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Aged, Combined Modality Therapy, Immunosuppressive Agents, therapeutic use, Young Adult, Treatment Outcome
Référence
Lancet. 2024 09 21;404(10458):1107-1118